LifeStance Health Group, Inc. (NASDAQ:LFST) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analyst sentiment is moderately bullish: Eleven analysts give LifeStance Health Group a consensus “Moderate Buy” rating, with six buys, one strong buy and four holds. The average 12-month price target is $12.63, while recent targets range up to $18.
• LifeStance reported quarterly EPS of $0.06 versus the $0.03 consensus estimate, while revenue rose 26.1% year over year to $435.35 million, exceeding expectations.
• Insiders have been selling: Company insiders sold 14.7 million shares worth approximately $155.5 million over the past three months, although institutional investors own 85.5% of the stock.

LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are currently covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $12.6250.

Several equities analysts recently commented on the stock. Barclays increased their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an "overweight" rating in a research report on Tuesday, July 14th. KeyCorp raised their target price on LifeStance Health Group from $11.00 to $13.00 and gave the stock an "overweight" rating in a research note on Monday, July 13th. BTIG Research lifted their price target on LifeStance Health Group from $16.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday, August 19th. Weiss Ratings raised LifeStance Health Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, August 11th. Finally, Wall Street Zen lowered LifeStance Health Group from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 5th.

Insider Buying and Selling at LifeStance Health Group

In other news, Director Robert Bessler sold 894,337 shares of the company's stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $10.13, for a total value of $9,059,633.81. Following the sale, the director owned 539,763 shares in the company, valued at $5,467,799.19. This represents a 62.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CTO Vukasin Paunovich sold 42,067 shares of the company's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total value of $541,402.29. Following the completion of the sale, the chief technology officer owned 205,379 shares in the company, valued at $2,643,227.73. The trade was a 17.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 14,671,917 shares of company stock valued at $155,493,415 in the last three months. Company insiders own 3.50% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Royal Bank of Canada boosted its position in LifeStance Health Group by 63.4% in the 1st quarter. Royal Bank of Canada now owns 70,248 shares of the company's stock worth $468,000 after purchasing an additional 27,244 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of LifeStance Health Group by 223.0% in the 1st quarter. AQR Capital Management LLC now owns 51,500 shares of the company's stock valued at $343,000 after purchasing an additional 35,554 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in LifeStance Health Group by 3.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company's stock worth $952,000 after buying an additional 4,169 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in LifeStance Health Group by 1.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company's stock worth $4,100,000 after buying an additional 11,331 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in LifeStance Health Group by 10.2% during the second quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company's stock valued at $2,847,000 after buying an additional 51,154 shares during the period. 85.50% of the stock is owned by institutional investors and hedge funds.

LifeStance Health Group Trading Down 1.4%

NASDAQ LFST opened at $12.62 on Thursday. LifeStance Health Group has a 52 week low of $4.77 and a 52 week high of $13.15. The company has a 50 day moving average price of $11.60 and a 200 day moving average price of $8.93. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.18. The firm has a market cap of $4.89 billion, a PE ratio of 97.08 and a beta of 1.22.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The business had revenue of $435.35 million for the quarter, compared to analyst estimates of $414.58 million. During the same period in the previous year, the company earned ($0.01) earnings per share. The business's revenue for the quarter was up 26.1% on a year-over-year basis. As a group, sell-side analysts forecast that LifeStance Health Group will post 0.16 EPS for the current fiscal year.

LifeStance Health Group Company Profile

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.